LivaNova (NASDAQ: LIVN) was upgraded by Zacks Investment Research from a “hold” rating to a “strong buy” rating in a note issued to investors on Wednesday, Zacks.com reports. The company currently has a target price of $ 96.00 on the stock. Zacks Investment Research’s target price would suggest a potential rise of 18.40% from the current share price.
According to Zacks, “LivaNova PLC is a medical technology company focused on the treatment of cardiovascular disease and neuromodulation. The company’s business units consist of heart rhythm management, cardiac surgery and neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. “
LIVN has been the subject of several other research reports. Robert W. Baird raised his price target on LivaNova from $ 100.00 to $ 105.00 and gave the stock an “outperformance” rating in a research report published on Tuesday August 17th. They noted that the move was an appraisal call. Needham & Company LLC increased its target price on LivaNova from $ 104.00 to $ 117.00 and gave the stock a “buy” rating in a research report on Friday, August 20. Finally, Piper Sandler lowered her price target on LivaNova from $ 99.00 to $ 98.00 and set an “overweight” rating for the company in a research report published on Tuesday, June 1. One investment analyst gave the stock a conservation rating, three assigned a buy rating, and one gave the company a high buy rating. According to MarketBeat.com, the company currently has an average “Buy” rating and a consensus price target of $ 100.00.
LivaNova shares opened at $ 81.08 on Wednesday. The company has a current ratio of 1.15, a quick ratio of 0.97, and a debt ratio of 0.41. The company has a market cap of $ 3.97 billion, a P / E ratio of -10.41 and a beta of 0.90. The company has a fifty-day simple moving average of $ 82.81 and a two-hundred-day simple moving average of $ 81.64. LivaNova has a 12-month low of $ 42.99 and a 12-month high of $ 90.25.
LivaNova (NASDAQ: LIVN) last announced its quarterly earnings data on Wednesday, July 28. The company reported EPS of $ 0.52 for the quarter, beating the consensus estimate of $ 0.33 by $ 0.19. The company posted revenue of $ 264.50 million in the quarter, compared to analysts’ estimate of $ 241.73 million. LivaNova recorded a positive return on equity of 8.44% and a negative net margin of 37.15%. Analysts expect LivaNova to post earnings per share of 1.57 for the current year.
In related news, director Daniel Jeffrey Moore sold 1,000 shares of the company in a transaction that took place on Wednesday, September 1. The stock was sold at an average price of $ 82.40, for a total trade of $ 82,400.00. Following the completion of the transaction, the director now directly owns 31,630 shares of the company, valued at approximately $ 2,606,312. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.37% of the company’s shares.
A number of hedge funds and other institutional investors have recently bought and sold shares. Bank of America Corp DE increased its stake in LivaNova by 1.0% in the 2nd quarter. Bank of America Corp DE now owns 738,329 shares of the company valued at $ 62,101,000 after purchasing an additional 7,486 shares in the last quarter. Parametric Portfolio Associates LLC increased its stake in LivaNova shares by 14.7% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 42,147 shares of the company valued at $ 3,545,000 after acquiring an additional 5,414 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new equity stake in LivaNova during the second quarter for a value of approximately $ 331,000. Marshall Wace North America LP increased its stake in LivaNova shares by 16.7% during the second quarter. Marshall Wace North America LP now owns 274,061 shares of the company valued at $ 23,051,000 after acquiring an additional 39,253 shares during the last quarter. Finally, Morgan Stanley increased its stake in LivaNova shares by 0.8% during the second quarter. Morgan Stanley now owns 53,468 shares of the company valued at $ 4,497,000 after acquiring 428 additional shares in the last quarter. 94.97% of the shares are currently held by institutional investors.
LivaNova Company Profile
LivaNova Plc is a global medical technology company dedicated to the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the cardiovascular and neuromodulation segments. The Cardiovascular segment develops, produces and sells cardiopulmonary products, heart valves and circulatory support products.
Further Reading: Trading Signals Using Bollinger Bands
Get a Free Copy of Zacks’ Research Report on LivaNova (LIVN)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in LivaNova now?
Before you consider LivaNova, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the wider market takes over … and LivaNova was not on the list.
While LivaNova currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks to be better buys.
See the 5 actions here